KR930703303A - 1, 4-벤조티아제핀 유도체 - Google Patents

1, 4-벤조티아제핀 유도체

Info

Publication number
KR930703303A
KR930703303A KR1019930701942A KR930701942A KR930703303A KR 930703303 A KR930703303 A KR 930703303A KR 1019930701942 A KR1019930701942 A KR 1019930701942A KR 930701942 A KR930701942 A KR 930701942A KR 930703303 A KR930703303 A KR 930703303A
Authority
KR
South Korea
Prior art keywords
lower alkoxy
substituent
group
alkoxy group
phenyl group
Prior art date
Application number
KR1019930701942A
Other languages
English (en)
Other versions
KR0165131B1 (ko
Inventor
노보루 가네꼬
다쓰시 오오사와
데루유끼 사까이
히데오 오오따
Original Assignee
노보루 가네꼬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보루 가네꼬 filed Critical 노보루 가네꼬
Publication of KR930703303A publication Critical patent/KR930703303A/ko
Application granted granted Critical
Publication of KR0165131B1 publication Critical patent/KR0165131B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

[목적]
본 발명의 목적은 심장억제 작용을 수반하지 않고 심근의 KD(동력학적 세포사)-억제 작용을 갖는 화합물을 제공하는 것이다.
[구성]
하기 식[Ⅰ]로 표시되는 1,4-벤조티아제핀 유도체 또는 그의 약제학적으로 허용되는 염.
식중, 각 치환기는 다음과 같이 정의된다; R은 H 또는 C1-C3저급 알콕시기를 나타내고; X는 0또는 H2를 나타내며; n은 1또는 2를 나타내고; R1은 H, 치환기가 OH 또는 C1-C3저급 알콕시기인 치환된 페닐기,
(여기에서 R2는 C1-C3아실기이다.)를 나타내며;PH는 페닐기를 나타낸다.

Description

1,4-벤조티아제핀 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 하기 식[Ⅰ]로 표시되는 1,4-벤조티아제핀 유도체 또는 그의 약제학적으로 허용되는 염.
  3. 식중, 각 치환기는 다음과 같이 정의된다; R은 H또는 C1-C3저급 알콕시기를 나타내고; X는 0또는 H2를 나타내며; n은 1또는 2를 나타내고;R1은 H, 치환기가 OH 또는 C1-C3저급 알콕시기인 치환된 페닐기,
  5. (여기에서 R2는 C1-C3아실기이다.)를 나타내며; PH는 페닐기를 나타낸다.
  6. 하기 식[Ⅰ]로 표시되는 1,4-벤조티아제핀 유도체 또는 그의 약제학적으로 허용되는 염의 1종 이상을 유효 성분으로서 함유하는, 심근 괴사 억제용 의약.
  8. 식중, 각 치환기는 다음과 같이 정의된다; R은 H또는 C1-C3저급 알콕시기를 나타내고; X는 0또는 H2를 나타내며:n 은 1또는 2를 나타내고; R1은 H, 치환기가 OH 또는 C1-C3저급 알콕시기인 치환된 페닐기.
  10. (여기에서 R2는 C1-C3아실기이다.)를 나타내며; PH는 페닐기를 나타낸다.
  11. 하기 식[Ⅰ]로 표시되는 1,4-벤조티아제핀 유도체 또는 그의 약제학적으로 허용되는 염의 1종 이상을 유효 성분으로서 함유하는, 급성 김근 경색 방지용 의약.
  13. 식중, 각 치환기는 다음과 같이 정의된다; R은 H또는 C1-C3저급 알콕시기를 나타내고;X는 0또는 H2를 나타내며; n은 1또는 2를 나타내고; R1은 H, 치환기가 OH또는 C1-C3저급 알콕시기인 치환된 페닐기.
  15. (여기에서 R2는 C1-C3아실기이다.)를 나타내며; PH는 페닐기를 나타낸다.
  16. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930701942A 1990-12-28 1991-12-27 1,4-벤조티아제핀 유도체 KR0165131B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2416066A JP2703408B2 (ja) 1990-12-28 1990-12-28 １，４‐ベンゾチアゼピン誘導体
JP416066/90 1990-12-28
PCT/JP1991/001804 WO1992012148A1 (fr) 1990-12-28 1991-12-27 Derive de 1,4-benzothiazepine

Publications (2)

Publication Number Publication Date
KR930703303A true KR930703303A (ko) 1993-11-29
KR0165131B1 KR0165131B1 (ko) 1999-02-18

Family

ID=18524314

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701942A KR0165131B1 (ko) 1990-12-28 1991-12-27 1,4-벤조티아제핀 유도체

Country Status (13)

Country Link
US (1) US5416066A (ko)
EP (1) EP0565721B1 (ko)
JP (1) JP2703408B2 (ko)
KR (1) KR0165131B1 (ko)
CN (1) CN1028992C (ko)
AT (1) ATE125539T1 (ko)
AU (1) AU9107491A (ko)
CA (1) CA2098495C (ko)
DE (1) DE69111619T2 (ko)
DK (1) DK0565721T3 (ko)
RU (1) RU2089550C1 (ko)
WO (1) WO1992012148A1 (ko)
ZA (1) ZA9110166B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2148584A1 (en) * 1992-11-09 1994-05-26 John Rosindale Housley Therapeutic agents
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1147772B1 (en) * 1998-12-28 2006-01-04 Noboru Kaneko Use of 1,4-benzothiazepine derivatives for the preparation of a medicament FOR the TREATMENT OF ATRIAL FIBRILLATION
CA2373484C (en) 1999-05-19 2009-01-20 Noboru Kaneko Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs
AU2733301A (en) * 1999-12-29 2001-07-09 Glaxo Group Limited Methods and compositions related to modulators of annexin and cartilage homeostasis
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia METHODS USING TYPE 1 RYANODINE RECEPTOR
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20070219180A1 (en) * 2004-04-28 2007-09-20 Noboru Kaneko Muscle Relaxtion Accelerator and Therapeutic Agent for Muscular Tissue Diseases Such as Muscle Relaxation Failure
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2009026444A1 (en) * 2007-08-22 2009-02-26 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
ME01989B (me) 2008-03-03 2012-08-31 Servier Lab Postupak za proizvodnju benzotiazepina od gama-aminoalkilbenzena
KR101337244B1 (ko) 2009-02-25 2013-12-06 노보루 카네코 1,4-벤조티아제핀-1-옥사이드 유도체 및 이를 이용한 의약 조성물
WO2010120382A1 (en) 2009-04-15 2010-10-21 State Of Oregon By And Through The State Board Of Higher Education On Behalf Of Portland State University Compounds and methods for modulating activity of calcium release channels
CA2956699C (en) 2014-07-30 2020-09-29 Aetas Pharma Co., Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
US11426415B2 (en) 2017-03-06 2022-08-30 Washington University Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders
CN111447932A (zh) 2017-12-11 2020-07-24 埃塔斯制药株式会社 含有1,4-苯并硫氮杂*-1-氧化物衍生物的光学异构体的肾功能障碍的改善药

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794639A (en) * 1966-03-10 1974-02-26 Squibb & Sons Inc Benzoxazepines and benzothiazepines
ZA836994B (en) * 1982-09-30 1984-05-30 Robins Co Inc A H Fused aromatic oxazepinones and sulfur analogs thereof
DE3382028D1 (de) * 1982-09-30 1991-01-10 Robins Co Inc A H Kondensierte aromatische oxazepinone und sulphuranaloge, ihrer herstellung und verwendung als histamin-antagonist.
JPS6140651A (ja) * 1984-07-31 1986-02-26 Hitachi Ltd 記憶装置へのフアイル割当て方法および割当て決定装置
JP2871811B2 (ja) * 1990-02-28 1999-03-17 サントリー株式会社 縮合７員環系化合物
JP2935541B2 (ja) * 1990-06-28 1999-08-16 サントリー株式会社 縮合複素環化合物
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor

Also Published As

Publication number Publication date
EP0565721B1 (en) 1995-07-26
CN1063491A (zh) 1992-08-12
JP2703408B2 (ja) 1998-01-26
DE69111619D1 (de) 1995-08-31
RU2089550C1 (ru) 1997-09-10
CA2098495C (en) 1999-11-30
EP0565721A1 (en) 1993-10-20
DE69111619T2 (de) 1996-01-18
CN1028992C (zh) 1995-06-21
US5416066A (en) 1995-05-16
AU9107491A (en) 1992-08-17
ATE125539T1 (de) 1995-08-15
EP0565721A4 (en) 1994-06-01
WO1992012148A1 (fr) 1992-07-23
CA2098495A1 (en) 1992-06-29
JPH04230681A (ja) 1992-08-19
KR0165131B1 (ko) 1999-02-18
DK0565721T3 (da) 1995-11-06
ZA9110166B (en) 1992-09-30

Similar Documents

Publication Publication Date Title
KR930703303A (ko) 1, 4-벤조티아제핀 유도체
KR930002325A (ko) 피리미딘 유도체
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR950000728A (ko) 포스포네이트 뉴클레오티드 에스테르 유도체
ATE174899T1 (de) Zytotoxische stilben-derivate und diese enthaltende pharmazeutische zusammensetzungen
KR890016966A (ko) 신규 항바이러스제
DE69505968D1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
KR890012970A (ko) 테트라히드로 이소퀴놀린 유도체
KR960007592A (ko) 신규한 피롤로카바졸
KR950016722A (ko) Ldl 산화 및 죽상동맥경화증의 억제 방법
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
KR927003525A (ko) 술폰아닐리드 유도체 및 의약
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR910004191A (ko) 신질환치료제
KR900001715A (ko) Bu-3608 유도체
KR950702530A (ko) 프로스타글란딘 유도체
KR920701240A (ko) 글루타티온 유도체
KR890008121A (ko) 로다닌 유도체 및 약제학적 조성물
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
MX9206930A (es) Nuevos compuestos
KR960700245A (ko) 메토트렉세이트 유도체[methotrexate derivative]
KR930702339A (ko) 에폭시숙시남산 유도체
KR890012973A (ko) 이미다졸 유도체
KR890003718A (ko) N- 알킬벤젠 술포닐 카르바모일-5- 클로로이소티아졸 유도체 및 살미생물제
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100825

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee